Abstract： Objective： To observe the effect of Qili Qiangxin capsules combined with western medicine on myocardial perfusion and heart function of patients with acute myocardial infarction(AMI) after percutaneous coronary intervention(PCI). Methods：A total of 80 cases of AMI patients undergoing PCI were selected and divided into the observation group and the control group according to the random number table method， 40 cases in each group. The control group was treated with western medicine，and the observation group was additionally treated with Qili Qiangxin capsules based on the treatment of the control group. Both groups were treated for three months. Clinical effects and incidences of adverse reactions in the two groups were compared. Chinese medicine syndrome scores，TIMI blood flow classification，heart function indexes as well as apolipoprotein CⅢ(ApoCⅢ)，matrix metalloproteinase-9(MMP-9) and carbohydrate antigen 125(CA125) in serum in the two groups were compared before and after treatment. Results：The total effective rate was 92.50% in the observation group， higher than that of 70.00% in the control group(P＜0.05). After treatment， Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment(P＜0.05)，and the score in the observation group was lower than that in the control group(P＜0.05). TIMI blood flow classification in the observation group was better than that in the control group(P＜0.05)；The blood flow acquisition rate of grade 3 TIMI was 62.50% in the observation group，higher than that of 37.50% in the control group(P＜0.05). After treatment， left ventricular ejection fraction(LVEF)， cardiac output(CO)， cardiac index(CI) and stroke volume(SV) in the two groups were increased when compared with those before treatment(P＜ 0.05)， and left ventricular end systolic diameter(LVESD) and left ventricular end diastolic diameter(LVEDD) were decreased (P＜0.05)；LVEF，CO，CI and SV in the observation group were higher than those in the control group(P＜0.05)，and LVESD and LVEDD were shorter(P＜0.05). After treatment，the levels of ApoCⅢ，MMP-9 and CA125 in serum in the two groups were decreased when compared with those before treatment(P＜0.05)，and the above levels in the observation group were lower than those in the control group(P＜0.05). The incidence of adverse reactions was 10.00% in the observation group and 20.00% in the control group，there being no significant difference between the two groups(P＞0.05). Conclusion：Based on western medicine treatment，the additional application of Qili Qiangxin capsules for patients with AMI after PCI can improve their clinical symptoms，myocardial perfusion and heart function，and reduce expressions of ApoCⅢ，MMP-9 and CA125 in serum with good safety.